-
A Phase 1 Open Label Multi-Arm Multicenter Study of MK-4830 as Monotherapy and in Combination with Pembrolizumab for Participants with Advanced Solid Tumors
This is a first-in-human (FIH), dose escalation, and dose finding trial to assess the safety and tolerability of MK-4830, both as monotherapy and as combination ...Phase
Interventional
-
STAMP: Surgically Treated Adjuvant Merkel cell Carcinoma with Pembrolizumab a Phase III Trial (ECOG EA6174)
This phase III trial studies how well pembrolizumab works compared to standard of care observation in treating patients with stage I-III Merkel cell cancer that ...Phase
Interventional
-
A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant
The current study is being conducted to evaluate the MRD negativity conversion rate following the addition of daratumumab to lenalidomide, when administered as maintenance treatment ...Phase
Interventional
-
An open-label phase I multi-center study to determine the recommended dose of the chimeric antigen receptor T-cell treatment CYAD-211 after a non-myeloablative preconditioning chemotherapy in multiple myeloma patients with relapsed or refractory disease
The purpose of the study is to determine the safety and tolerability of the investigational product CYAD-211 when administered as a single infusion after a ...Phase
Interventional
-
A Phase 1b Study of Nivolumab in Patients with Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)
We want to know the safety and tolerability of the anti-programmed death 1 (PD-1) antibody nivolumab at different dose levels for patients with autoimmune disorders ...Phase
Interventional
-
A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma (KEYNOTE-U02): Substudy 02A
The purpose of the study is to determine the safety and tolerability of investigational treatment combinations with or without pembrolizumab or pembrolizumab alone for the ...Phase
Interventional
-
A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of lnvestigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma (KEYNOTE-U02): Substudy 02B Ph 1/2 Substudy of 1L Oncological Treatment(s) in Advanced MEL
The purpose of the study is to assess the efficacy of investigational treatment arms (pembrolizumab monotherapy or a unique pembrolizumab-based/ non-pembrolizumab-based combination) in participants with ...Phase
Interventional
-
Site for ARST1431: A Randomized Phase 3 Study of Vincristine Dactinomycin Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) versus VAC/VI plus Temsirolimus (TORI Torisel NSC# 683864) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
The purpose of the study is to determine the outcome for people with intermediate risk Rhabdomyosarcoma (RMS) by adding an experimental drug called temsirolimus to ...Phase
Interventional
-
A Phase 3 Trial Investigating Blinatumomab (IND#117467 NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma(B-LLy)
The purpose of the trial is to determine the safety and efficacy of the investigational medicine, blinatumomab plus standard treatment for patients who have Standard ...Phase
Interventional
-
ACNS1831: A Phase 3 Randomized Study of Selumetinib (IND # 77782) versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)
The purpose of the study is to compare the efficacy of two treatments. The purpose is to determine whether the efficacy of treatment with selumetinib ...Phase
Interventional
